본문 바로가기
KERD
논문KCI 등재

Low-Dose Acetazolamide in the Treatment of Premenstrual Dysphoric Disorder: A Case Series

Georgios D. Kotzalidis|Gabriele Sani|Isabella Panaccione|Alessio Simonetti|Lavinia De Chiara|Antonio Del Casale|Elisa Ambrosi|Flavia Napoletano|Delfina Janiri|Emanuela Danese|Nicoletta Girardi|Chiara Rapinesi|Daniele Serata|Giovanni Manfredi|Alexia E. Koukopoulos|Gloria Angeletti|Ferdinando Nicoletti|Paolo Girardi
대한신경정신의학회 (Korean Neuropsychiatric Association)|2014.01|PSYCHIATRY INVESTIGATION|제11권 제1호|pp. 95-101

0

조회

0

다운로드

0

인용

0

참고문헌

키워드

Premenstrual dysphoric disorderAcetazolamideSulfonamide diureticsGABA transmission
주제분류정신과학

초록

The treatment of premenstrual dysphoric disorder (PMDD) is far from satisfactory, as there is a high proportion of patients who do notrespond to conventional treatment. The antidiuretic sulfonamide, acetazolamide, inhibits carbonic anhydrase and potentiates GABAergictransmission; the latter is putatively involved in PMDD. We therefore tried acetazolamide in a series of women with intractable PMDD. Here, we describe a series of eight women diagnosed with DSM-IV-TR PMDD, five of whom had comorbidity with a mood disorder andone with an anxiety disorder, who were resistant to treatment and responded with symptom disappearance after being added-on 125mg/day acetazolamide for 7-10 days prior to menses each month. Patients were free from premenstrual symptoms at the 12-month follow-up. We suggest that acetazolamide may be used to improve symptoms of PMDD in cases not responding to other treatments. GABAergicmechanisms may be involved in counteracting PMDD symptoms.

Abstract

The treatment of premenstrual dysphoric disorder (PMDD) is far from satisfactory, as there is a high proportion of patients who do notrespond to conventional treatment. The antidiuretic sulfonamide, acetazolamide, inhibits carbonic anhydrase and potentiates GABAergictransmission; the latter is putatively involved in PMDD. We therefore tried acetazolamide in a series of women with intractable PMDD. Here, we describe a series of eight women diagnosed with DSM-IV-TR PMDD, five of whom had comorbidity with a mood disorder andone with an anxiety disorder, who were resistant to treatment and responded with symptom disappearance after being added-on 125mg/day acetazolamide for 7-10 days prior to menses each month. Patients were free from premenstrual symptoms at the 12-month follow-up. We suggest that acetazolamide may be used to improve symptoms of PMDD in cases not responding to other treatments. GABAergicmechanisms may be involved in counteracting PMDD symptoms.

참고문헌 (69)

  1. Johnson SR, "Epidemiology of premenstrual symptoms in a nonclinical sample. I. Prevalence, natural history and help-seeking behavior", J Reprod Med, 33, pp.340~346 (1988)
  2. Hylan T, "The impact of premenstrual symptomatology on functioning and treatment-seeking behavior: experience from the United States, United Kingdom, and France", J Womens Health Gend Based Med, 8, pp.1043~1052 (1999)
  3. Borenstein JE, "Health and economic impact of the premenstrual syndrome", J Reprod Med, 48, pp.515~524 (2003)
  4. Borenstein JE, "Differences in symptom scores and health outcomes in premenstrual syndrome", J Womens Health (Larchmt), 16, pp.1139~1144 (2007)
  5. Yang M, "Burden of premenstrual dysphoric disorder on health-related quality of life", J Womens Health (Larchmt), 17, pp.113~121 (2008)
  6. American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV)" (1994), American Psychiatric Association
  7. Yonkers KA, "Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group", JAMA, 278, pp.983~988 (1997)
  8. Pearlstein TB, "Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo", J Clin Psychiatry, 61, pp.101~109 (2000)
  9. Frank RT, "The hormonal causes of premenstrual tension", Arch Neurol Psychiatry, 26, pp.1053~1057 (1931)
  10. Horney K, "Die prämenstruellen Verstimmungen", Zeitschrift für psychoanalytische Pädagogik, 5, pp.1~7 (1931)
  11. Greene R, "The premenstrual syndrome", Br Med J, 1, pp.1007~1014 (1953)
  12. Halbreich U, "Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies", Gynecol Endocrinol, 23, pp.123~130 (2007)
  13. American Psychiatric Association, "Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition-Revised (DSM-III-R)" (1987), American Psychiatric Association
  14. World Health Organization, "ICD-10: International Classification of Diseases and Related Health Problems (Tenth Revision)" (1992), World Health Organization
  15. American College of Obstetricians and Gynecologists, "Premenstrual Syndrome" (2000), American College of Obstetricians and Gynecologists
  16. Royal College of Obstetricians and Gynaecologists, "Management of Premenstrual Syndrome Green-top Guideline No 48" (2007), Royal College of Obstetricians and Gynaecologists
  17. O’Brien PM, "Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus", Arch Womens Ment Health, 14, pp.13~21 (2011)
  18. Pearlstein T, "The Premenstrual Syndromes:PMS and PMDD", pp.37~47 (2007), Informa Healthcare
  19. Shah NR, "Selective serotonin reuptake inhibitors for premenstrual syndrome and premenstrual dysphoric disorder: a meta-analysis", Obstet Gynecol, 111, pp.1175~1182 (2008)
  20. Brown J, "Selective serotonin reuptake inhibitors for premenstrual syndrome", Cochrane Database Syst Rev, (2), pp.CD001396~ (2009)
  21. Halbreich U, "Selective serotonin reuptake inhibitors and initial oral contraceptives for the treatment of PMDD: effective but not enough", CNS Spectr, 13, pp.566~572 (2008)
  22. Eriksson E, "The serotonin reuptake inhibitor paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome", Neuropsychopharmacology, 12, pp.167~176 (1995)
  23. Pearlstein TB, "Comparison of fluoxetine, buproprion, and placebo in the treatment of premenstrual dysphoric disorder", J Clin Psychopharmacol, 17, pp.261~266 (1997)
  24. Freeman EW, "Differential response to antidepressants in women with premenstrual syndrome", premenstrual dysphoric disorder: a randomized controlled trial, 1999, pp.56, 932~939
  25. Steiner M, "Treatment of premenstrual tension with lithium carbonate. A pilot study", Acta Psychiatr Scand, 61, pp.96~102 (1980)
  26. Smith S, "Treatment of premenstrual syndrome with alprazolam: results of a double-blind, placebo-controlled, randomized crossover clinical trial", Obstet Gynecol, 70, pp.37~43 (1987)
  27. Harrison WM, "Treatment of premenstrual dysphoria with alprazolam. A controlled study", Arch Gen Psychiatry, 47, pp.270~275 (1990)
  28. Freeman EW, "A double-blind trail of oral progesterone, alprazolam, and placebo in treatment of severe premenstrual syndrome", JAMA, 274, pp.51~57 (1995)
  29. Schmidt P, "Alprazolam in the treatment of premenstrual syndrome. A double-blind, placebo-controlled trial", Arch Gen Psychiatry, 50, pp.467~473 (1993)
  30. Landen M, "Compounds with affinity for serotonergic receptors in the treatment of premenstrual dysphoria: a comparison of buspirone, nefazodone and placebo", Psychopharmacology (Berl), 155, pp.292~298 (2001)
  31. Rickels K, "Buspirone in treatment of premenstrual syndrome", Lancet, 1, pp.777~ (1989)
  32. Freeman EW, "Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder", Eur J Contracept Reprod Health Care, 7(suppl 3), pp.27~34 (2002)
  33. Lopez LM, "Oral contraceptives containing drospirenone for premenstrual syndrome", Cochrane Database Syst Rev, (2), pp.CD006586~ (2009)
  34. Rapkin AJ, "Drospirenone: a novel progestin", Expert Opin Pharmacother, 8, pp.989~999 (2007)
  35. Sundström I, "Treatment of premenstrual syndrome with gonadotropin-releasing hormone agonist in a low dose regimen", Acta Obstet Gynecol Scand, 78, pp.891~899 (1999)
  36. Halbreich U, "Elimination of ovulation and menstrual cyclicity (with danazol) improves dysphoric premenstrual syndromes", Fertil Steril, 56, pp.1066~1069 (1991)
  37. Casper RF, "The effect of hysterectomy and bilateral oophorectomy in women with severe premenstrual syndrome", Am J Obstet Gynecol, 162, pp.105~109 (1990)
  38. Casson P, "Lasting response to ovariectomy in severe intractable premenstrual syndrome", Am J Obstet Gynecol, 162, pp.99~105 (1990)
  39. Wang M, "Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study", Acta Obstet Gynecol Scand, 74, pp.803~808 (1995)
  40. Mira M, "Mefenamic acid in the treatment of premenstrual syndrome", Obstet Gynecol, 68, pp.395~398 (1986)
  41. Facchinetti F, "Naproxen sodium in the treatment of premenstrual symptoms. A placebo-controlled study", Gynecol Obstet Invest, 28, pp.205~208 (1989)
  42. Steege JF, "The effects of aerobic exercise on premenstrual symptoms in middle-aged women: a preliminary study", J Psychosom Res, 37, pp.127~133 (1993)
  43. Blake F, "Cognitive therapy for premenstrual syndrome: a controlled trial", J Psychosom Res, 45, pp.307~318 (1998)
  44. Christensen AP, "The efficacy of cognitive behaviour therapy in treating premenstrual dysphoric changes", J Affect Disord, 33, pp.57~63 (1995)
  45. Halmi P, "Expression of carbonic anhydrases II, IV, VII, VIII and XII in rat brain after kainic acid induced status epilepticus", Neurochem Int, 48, pp.24~30 (2006)
  46. Thiry A, "Exploration of the binding mode of indanesulfonamides as selective inhibitors of human carbonic anhydrase type VII by targeting Lys 91", ChemMedChem, 2, pp.1273~1280 (2007)
  47. Lovick TA, "Plasticity of GABAA receptor subunit expression during the oestrous cycle of the rat: implications for premenstrual syndrome in women", Exp Physiol, 91, pp.655~660 (2006)
  48. Reiss WG, "Acetazolamide in the treatment of seizures", Ann Pharmacother, 30, pp.514~519 (1996)
  49. Lim LL, "Acetazolamide in women with catamenial epilepsy", Epilepsia, 42, pp.746~749 (2001)
  50. Stewart WC, "Perspectives in the medical treatment of glaucoma", Curr Opin Ophthalmol, 10, pp.99~108 (1999)
  51. Wandstrat TL, "Pseudotumor cerebri responsive to acetazolamide", Ann Pharmacother, 29, pp.318~ (1995)
  52. Richalet JP, "Acetazolamide: a treatment for chronic mountain sickness", Am J Respir Crit Care Med, 172, pp.1427~1433 (2005)
  53. White DP, "Central sleep apnea. Improvement with acetazolamide therapy", Arch Intern Med, 142, pp.1816~1819 (1982)
  54. Matthews E, "Acetazolamide efficacy in hypokalemic periodic paralysis and the predictive role of genotype", Neurology, 77, pp.1960~1964 (2011)
  55. Inoue H, "Antipsychotic and prophylactic effects of acetazolamide (Diamox) on atypical psychosis", Folia Psychiatr Neurol Jpn, 38, pp.425~436 (1984)
  56. Factor SA, "Acetazolamide therapy of menstrual-related fluctuations in Parkinson’s disease", Mov Disord, 8, pp.240~241 (1993)
  57. Hayes SG, "Acetazolamide in bipolar affective disorders", Ann Clin Psychiatry, 6, pp.91~98 (1994)
  58. Brandt C, "Acetazolamide in the treatment of acute mania. A case report", Neuropsychobiology, 38, pp.202~203 (1998)
  59. Freeman EW, "Reliability and validity of a daily diary for premenstrual syndrome", Psychiatry Res, 65, pp.97~106 (1996)
  60. Pompili M, "TEMPS-A (Rome): psychometric validation of affective temperaments in clinically well subjects in mid- and south Italy", J Affect Disord, 107, pp.63~75 (2008)
  61. Kendell SF, "GABA and glutamate systems as therapeutic targets in depression and mood disorders", Expert Opin Ther Targets, 9, pp.153~168 (2005)
  62. Kim BG, "Modulation of presynaptic GABA(A) receptors by endogenous neurosteroids", Br J Pharmacol, 164, pp.1698~1710 (2011)
  63. Choi J, "Association of seasonality and premenstrual symptoms in bipolar I and bipolar II disorders", J Affect Disord, 129, pp.313~316 (2011)
  64. Dodgson SJ, "Topiramate as an inhibitor of carbonic anhydrase isoenzymes", Epilepsia, 41(Suppl 1), pp.S35~S39 (2000)
  65. Shank RP, "Carbonic anhydrase inhibition. Insight into the characteristics of zonisamide, topiramate, and the sulfamide cognate of topiramate", J Enzyme Inhib Med Chem, 23, pp.271~276 (2008)
  66. Koukopoulos A, "Endogenous and exogenous cyclicity and temperament in bipolar disorder: review, new data and hypotheses", J Affect Disord, 96, pp.165~175 (2006)
  67. Koukopoulos A, "Melancholia agitata and mixed depression", Acta Psychiatr Scand Suppl, 433, pp.50~57 (2007)
  68. Joffe H, "Estrogen, serotonin, and mood disturbance: where is the therapeutic bridge?", Biol Psychiatry, 44, pp.798~811 (1998)
  69. Steiner M, "Hormones and mood: from menarche to menopause and beyond", J Affect Disord, 74, pp.67~83 (2003)

관련 논문AI추천

PHARMACOTHERAPY FOR PREMENSTRUAL DYSPHORIC DISORDER: A META-ANALYSIS OF PHASE 3 TRIALS김탁, 김선행, 김성민, 박나윤, 박현태, 신정호, 염선경, 유민지, 이경욱, 허준용대한산부인과학회 · Obstetrics & Gynecology Science2012 · 제55권 제03호Oxaloacetate reduces emotional symptoms in premenstrual syndrome (PMS): results of a placebocontrolled, cross-over clinical trialAlan Cash, John Humiston, Lisa Tully대한산부인과학회 · Obstetrics & Gynecology Science2020 · 제63권 제2호Effect of calcium on premenstrual syndrome: A double-blind randomized clinical trialEnsiyeh Jenabi, Fahimeh Ezzati Araste, Fatemeh Shobeiri, Mansour Nazari, Reihaneh Ebrahimi대한산부인과학회 · Obstetrics & Gynecology Science2017 · 제60권 제1호A systematic review of the role of vitamin D and calcium in premenstrual syndromeFatemeh Abdi, Fatemeh Sadat Rahnemaie, Gity Ozgoli대한산부인과학회 · Obstetrics & Gynecology Science2019 · 제62권 제2호뉴로피드백 훈련이 월경 전 불쾌장애의 정서적, 행동적 및 신체적 증상에 미치는 효과김현택, 손정락, 오은혜한국건강심리학회 · 한국심리학회지: 건강2009 · 제14권 제4호Premenstrual Syndrome and Premenstrual Dysphoric Disorder in Perimenopausal Women김예솔, 김태희, 박준식, 이아룸, 이해혁, 전동수, 정수호대한폐경학회 · 대한폐경학회지2014 · 제20권 제2호

이 간행물의 다른 논문 (7건)

Korean Medication Algorithm for Depressive Disorder: Comparisons with Other Treatment Guidelines홍진표, 전덕인, 우영섭, 박영민, 서정석, 김원, 정종현, 민경준, 홍정완, 박원명, 송후림, 이황빈, 임은성, 왕희령pp. 1-11A Cluster Model of Temperament as an Indicator of Antidepressant Response and Symptom Severity in Major DepressionEsa Leinonen, Eija Setälä-Soikkeli, Merja Viikki, Ari Illi, Olli Kampman, Vesa Paavonenpp. 18-23Risk Factors for Suicidal Ideation among Patients with Complex Regional Pain Syndrome황재연, 김성년, 강도형, 이도형, 변민수, 장준환, 노은정, 김용철pp. 32-38Development of the Ubiquitous Spaced Retrieval-Based Memory Advancement and Rehabilitation Training ProgramKyusoo Oh, 김기웅, 유수영, Eunhye Kim, Yeon Kyung Chi, 한지원, Tae Hui Kim, Ki-Hwan Ahn, Yeon-Joo Sonpp. 52-58Neuropsychological and Behavioral Profiles in Attention-Deficit Hyperactivity Disorder Children of Parents with a History of Mood Disorders: A Pilot Study박은진, Kang-E M Hong, 유희정, 박미라, Young Hui Yang, 박수빈, 하규섭, 강제욱pp. 65-75
원문 보기